ReviewDiscover nano2026
Machine learning-enhanced nano-QSAR and multiscale modeling for predictive nanomedicine: applications in herbal therapeutics and neglected tropical diseases.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanomedicine has transformed targeted drug delivery, yet the complexity of nano-bio interactions continues to hinder rational nanoparticle design. Predictive computational approaches, particularly machine learning (ML), nano-quantitative structure-activity relationships (nano-QSAR), and multiscale modeling, emerge as essential tools for understanding and optimizing nanoparticle behavior across biological environments. This review synthesizes advances in nano-specific descriptors, classical and deep learning frameworks, physics-informed hybrid models, and simulations spanning quantum, atomistic, and tissue-level scales. We highlight two application domains where these strategies show distinct translational promise: herbal nanomedicine, where computational modeling supports the design of phytochemical-loaded nanoparticles with improved solubility, stability, and targeting, and neglected tropical diseases, where predictive tools enable optimization of macrophage targeting, parasite niche penetration, and performance under resource-limited conditions. Persistent challenges, including data scarcity, heterogeneity, limited reproducibility, and regulatory uncertainty, are critically examined. We propose future directions centered on standardized open datasets, foundation AI models, autonomous nanoparticle design, and patient-specific digital twin platforms. Collectively, these integrative computational strategies provide a roadmap for accelerating safe, effective, and context-adapted nanomedicine development. Integration of machine learning, nano-QSAR, and multiscale modeling enables predictive, rational design of nanomedicines for diverse disease applications.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.